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A large body of evidence suggests that serotoninergic
antidepressants such as clomipramine, fluvoxamine,
and fluoxetine are the most effective pharmacological
treatments of obsessive-compulsive disorders.'
The classic biochemical theory of major depression
hypothesises disturbances in serotoninergic or
catecholaminergic neurotransmission, or both. Until
now, however, no specific symptoms have been clearly
shown to orient with a selective antidepressant.2 In
addition to the depressive disorder, the underlying
personality may be assessed as a possible aid to the
therapeutic decision. Compulsive personality usually
pre-exists in patients developing obsessive-compulsive
disorder.'
We hypothesised that patients with a major depres-
sive episode and an underlying compulsive personality
would preferentially have serotoninergic depression
and hence respond to a serotoninergic antidepressant
such as fluvoxamine.4
Patients, methods, and results
We studied 46 outpatients who fulfilled DSM-III
criteria (Diagnostic and Statistical Manual of Mental
Disorders, Third Edition) for a major depressive episode3
and who also scored higher than 17 on the first 17 items
of the Hamilton depression scale. The patients were
among consecutive referrals to our department from
general practitioners. Twenty two of the 46 patients
had an underlying compulsive personality (DSM-III
criteria)3 as manifested by at least four of the following
five features: restricted ability to express warm and
tender emotions; perfectionism; insistence that others
must submit to his or her way of doing things;
excessive devotion to work and productivity; in-
decisiveness. The other 24 patients did not have a
compulsive personality (only one or no compulsive
feature).
The two study groups did not differ significantly in
age (mean 46-8 years (range 28-63) v 413 years (22-
64)), sex (12 men, 10 women v 12 men, 12 women),
weight, duration of current depressive episode,
previous treatment, medical or psychiatric history, or
baseline level of depressive symptoms. The study
lasted eight weeks and included assessments at baseline
and after two, four, and eight weeks of treatment with
the 24 item Hamilton depression scale and a subscale
for endogenomorphic depression. All side effects were
recorded. The initial dose of fluvoxamine was 100 mg
at bedtime, which could be increased to 200 mg from
the third week. Other psychotropic drugs were
excluded except for a low dose benzodiazepine anxioly-
tic or hypnotic, or both, if needed. The protocol was
approved by the ethics committee of the university
medical school and all patients gave informed consent.
Statistical analysis was by X2 test with the Yates
correction for small samples, one way analysis of
variance, and two way analysis of variance (compulsive
v non-compulsive, four replications) with repeated
measures. End point data in drop outs did not change
the conclusions and are not reported.
Ten patients dropped out of the study because of
lack of efficacy of the treatment or side effects (three
patients in the compulsive group, seven in the non-
compulsive group; (x2=0-84 p=0-36). To see whether
completing the study could be prognostic an analysis of
variance was performed on the basal Hamilton total
score. This two way analysis (completer v non-
completer, compulsive v non-compulsive) showed no
significant effect or interaction. The same analysis of
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Changes over time in Hamilton depression scores with fluvoxamine in
patients with major depressive episode with or without underlying
compulsive personality. Bars are 95% confidence intervals
Comparison of changes in Hamilton depression
scores over time showed significantly greater improve-
ment in the compulsive group after eight weeks of
treatment (F (3,32) = 10-65; p=00001) (figure). This
difference was even more pronounced on the subscale
for endogenomorphic depression (F (3,32) = 7 09;
p=00009), which had already shown a significant
difference between the groups after four weeks (p=
0-05). There was no significant difference between the
groups in the number of reported side effects (mainly
gastrointestinal; 12 patients in the compulsive group,
12 in the non-compulsive group; x2=0 01 df=1, p=
0 92). The mean final dose of fluvoxamine was 168-4
(SD 50 6)mg in the compulsive group and 179 4
(39-8)mg in the non-compulsive group (F=0-52; p=
0 48).
Comment
These results suggest that depressive patients with
an underlying compulsive personality respond better
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to a serotoninergic antidepressant such as fluvoxamine
than do depressive patients without an underlying
compulsive personality. This is important as the
personality ofa depressive patient can easily be assessed
for orientation with a selective type of compound. In
the past many studies have tried to predict treatment
response to selective antidepressants by using biological
markers such as the concentration of neurotransmitter
metabolites in urine or cerebrospinal fluid, with
controversial results.) Moreover, these methods entail
elaborate techniques for collecting body fluids and for
assay.
Finally, our finding that depressive patients with
a compulsive personality respond better to a sero-
toninergic antidepressant suggests some biochemical
similarity in central serotonin disturbance between this
subtype of depression and obsessive-compulsive
disorder.
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Nasal drops are a popular method of drug delivery to
the mucocolumnar epithelium of the nose. Drugs from
sympathomimetics to steroids have been given in this
way. Though insufflation by a metered spray has
become available, nasal drops properly applied in the
head down and forward position (Moffat's position)
have proved more effective in treating disease arising
in the osteomeatal complex.' As our understanding of
the key role of this complex in sinus disease increases,2
so the rationale for using nasal drops has been re-
asserted.
Treatment regimens usually prescribe a set number
of drops to each nostril, to be self administered by the
patient. The assumption is that a standard dose of the
drug will thus be delivered. Many patients, however,
have difficulty in sensing how many drops have entered
the nose. Clearly, if the therapeutic margin of the drug
is narrow safety margins may be exceeded.
Betamethasone sodium phosphate is a steroid pre-
paration used in nasal disease. It is normally prescribed
as two drops twice or three times daily in each nostril
with the patient in Moffat's position. The proprietary
product Betnesol (Glaxo Pharmaceuticals) utilises a
standard dropper nozzle mechanism that is common to
all current dropper products. It is designed to provide
a constant size drop. To assess the accuracy of this
system we recruited a group of healthy well informed
doctors as volunteers.
Subjects, methods, and results
Ten asymptomatic doctors took part. All knew of
the potential side effects of betamethasone and agreed
to be rigorous in the application of the drops. A
preweighed proprietary bottle of the drug (Betnesol)
was given to each volunteer with the instructions to
instil two drops into each nostril twice a day while
adopting Moffat's position. Each administration was
recorded. After 14 days the records were checked, the
bottles reweighed, and the total weight of drug used by
each volunteer thus calculated.
Manufacturer's data describe a standard drop weight
of 0025 mg betamethasone solution. To corroborate
this 10 drops formed under gravity from each of five
proprietary bottles were weighed, and the average
weight of the 50 drops was indeed 0 025 mg. Using
these data we calculated the notional average drops
used daily by each volunteer (table). All 10 volunteers
overused the drug, by a range of 41-338% (mean
132%). Seven volunteers reported difficulties in
sensing the number of drops entering the nose.
To help further explain the overuse we examined the
mechanism of drop formation. Whereas first drops
under gravity formed promptly, second drops took up
to three minutes to form and the tendency was to
squeeze the bottle. When 50 drops from five bottles
were formed by gentle squeezing the average weight
was 0-033 mg, an increase over gravity drops of 32%.
Total weight of drug used and average number ofdrops used daily by
10 volunteers using betamethasone nasal drops for 14 days
Total weight of
drug used (mg) Average No of drops daily












Given a well informed, asymptomatic group of
medical volunteers, drug overuse was the rule.
As there was no bias towards overuse to alleviate
symptoms the variability of results can be attributed to
the mechanism of drug delivery. It was clear from the
comments of the participants that accurate sensory
assessment of the number of drops instilled was
difficult. The inclination was to continue in the
delivery position until drops were felt in the nose. In
addition, the tendency to squeeze the bottle can greatly
increase the dose delivered. When properly adminis-
tered in Moffat's position drop solutions are still
superior to other methods of drug delivery in the
treatment of nasal disease. Nevertheless, if the drug
delivery system of a systemically active drug can be so
insensitive and variable, then development of a more
accurate system seems desirable.
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